Why Thousands of Donated Organs Are Discarded Each Year in the U.S.

In a country where the transplant waiting list routinely sits above six figures, it feels almost
unbelievable that donated organs still get tossed. Not “left on a counter” tossedmore like
“could have saved a life, but didn’t make it into an operating room” tossed.

The hard truth: organ donation is not a single moment of generosity. It’s a relay race run at
sprint speedICU teams, organ recovery teams, labs, flights, surgeons, coordinators, and a patient
who’s been fasting since yesterdaypassing a baton that expires faster than guacamole in July.
When any handoff fails (or the system nudges people to play it safe), usable organs can end up
discarded.

First, what does “discarded” actually mean?

In transplant data, “discarded” usually refers to an organ that was recovered for the purpose of
transplant but ultimately not transplanted. That’s different from:

• Not recovered: donation doesn’t proceed or organs aren’t recovered.
• Not authorized: the patient isn’t a donor or consent/authorization isn’t obtained.
• Recovered for research: sometimes organs are recovered for research rather than transplant.

When people say “thousands,” they’re not exaggerating. In a single recent pre-pandemic year, the
counts of recovered-but-not-transplanted organs included several thousand kidneys, plus hundreds
of livers and other organs. Kidneys are the headline-maker because they’re recovered frequently
and have the highest nonuse burdenmeaning a small percentage turns into a big number.

The problem isn’t one “bad decision”it’s a pile-up of friction

If organ discard were caused by one villain, we’d have solved it already. Instead, it’s a whole
cast: time pressure, imperfect information, inconsistent standards, logistical bottlenecks, and
incentives that unintentionally reward caution.

Reason #1: The offer chain is long, and every “no” burns time

One organ, dozens of offers, and a ticking clock

Organs are typically offered down a match list. Each transplant program evaluates the offer for a
specific candidate, considering blood type, size, urgency, compatibility, infection risk, expected
function, and how the organ “looks on paper” (labs, imaging, donor history).

The catch: the organ can be declinedagain and againfor reasons that are sometimes medical,
sometimes logistical, and sometimes institutional (like “we can’t staff a case at 2 a.m.”).
Meanwhile, the organ is aging in real time.

Variation between programs is massive

Studies have found wide variation in acceptance behavior across transplant centers. Some programs
routinely accept higher-risk organs (and do well with them), while others are more conservative.
That variation can turn “a perfectly reasonable organ” into “an organ that racks up declines,” and
that decline history can become its own red flag.

This is why you’ll hear insiders talk about an organ becoming “stigmatized.” Not because it
magically changed, but because a long decline trail can make the next program wonder what
everyone else saw that they’re missing.

Reason #2: Time and logistics can sabotage even a healthy-looking organ

Cold ischemia time: the organ’s “shelf life” problem

Organs don’t love being outside the body. Even on ice, time matters. The longer an organ spends
without blood flow, the higher the risk of complicationsespecially for kidneys (delayed graft
function) and livers (biliary injury in certain contexts).

Now add the real-world obstacles:

• Distance and transport: flights get delayed, couriers miss connections, weather happens.
• Operating room availability: trauma cases, emergencies, or staffing shortages can bump schedules.
• Surgeon availability: procurement and transplant are specialized; coverage isn’t infinite.
• Last-minute recipient issues: infection, instability, crossmatch concerns, or a sudden contraindication.

Yes, even the calendar can matter

Research has described a “weekend effect” in kidney procurement and discard: operational factors
(staffing, scheduling, transport coordination) can subtly increase the odds that a kidney ends up
not transplanted when logistics are harder.

Reason #3: We’re not always great at predicting which “imperfect” organs will succeed

Biopsy results: helpful… and sometimes misleading

For kidneys, procurement biopsies are a common source of controversy. A biopsy can reveal chronic
changes (scarring, vascular disease), but real-world biopsy quality varies: sampling error,
different staining/reading practices, and “interpretation drift” between pathologists.

Multiple analyses have highlighted biopsy findings as a frequent documented reason for kidney
discard. But here’s the uncomfortable part: there’s often overlap between the quality of kidneys
that get transplanted and those that get discarded. In other words, the discard pile can contain
organs that could have worked.

Acute kidney injury (AKI) in donors is a classic example

A donor’s creatinine can spike due to temporary injuryshock, medications, the physiology of
critical illness. Some kidneys with donor AKI recover function after transplant and perform well,
yet they may be declined more often because they look “scary” in the labs.

The data trend is clear: how organs are evaluated (and how risk is perceived) strongly shapes
nonuse. Sometimes the organ isn’t “bad”it’s just “uncertain,” and uncertainty is expensive when
outcomes are publicly tracked.

Reason #4: The system quietly encourages risk aversion

Public outcome reporting: sunlight plus unintended shadows

Public reporting and regulatory oversight exist for a good reason: patients deserve safety and
accountability. But when the metrics emphasize short-term outcomes without fully accounting for
organ complexity, programs can feel punished for taking reasonable risks.

Translation: a center might decline a marginal organ not because it can’t help a patient, but
because a single poor outcome could jeopardize ratings, inspections, or reputation. That’s not
“evil.” It’s human behavior in a high-stakes scoreboard environment.

Procurement organizations face pressure too

Federal policy over the last few years has pushed for stronger performance measurement of organ
recovery organizations, with the explicit goal of increasing transplantation and reducing
discards. That accountability is intended to raise the floorbut it can also create perverse
incentives if not designed carefully, like prioritizing recoveries that “count” while leaving
complex cases behind.

Reason #5: The donor pool is changingand the system is still adapting

The U.S. donor pool today includes more donation after circulatory death (DCD) donors and more
medically complex donors than in earlier eras. That’s not a critiqueit’s reality. It means more
organs land in the gray zone: potentially transplantable, but requiring specialized protocols,
machine perfusion, and centers willing to accept added uncertainty.

Some recent analyses suggest kidney nonuse climbed notably in the early 2020s, reaching roughly
the high 20% range in certain datasets. That doesn’t mean “one in four kidneys is junk.” It means
the system is still figuring out how to safely use more kidneys that used to be considered too
riskyor too annoying to coordinate at 3 a.m.

Reason #6: Different organs fail for different reasons

Kidneys: the “high-volume, high-variation” organ

Kidneys are recovered frequently, and they can often be transplanted successfully even when they
look imperfectolder donors, hypertension, diabetes history, high KDPI, donor AKI, hepatitis C
positivity (with modern antiviral therapy). But they are also declined frequently, and the
accumulation of declines itself can push a kidney toward discard.

Livers: quality is harder to fake

Livers can be unforgiving when steatosis (fatty change), warm ischemia, or DCD-related injury
reaches certain thresholds. Programs may decline when the risk of biliary complications or early
graft dysfunction feels too high. That said, machine perfusion and viability testing have shown
real promise in “rescuing” livers that might otherwise be discarded.

Lungs: utilization has long been limitedbut technology is expanding the pool

Lungs are particularly sensitive to donor management, infection risk, aspiration, and oxygenation
issues. Historically, many lungs were discarded because they didn’t meet strict criteria.
Ex vivo lung perfusion (EVLP) has helped some centers evaluate and rehabilitate marginal lungs,
increasing the number that can be safely transplanted.

Hearts: DCD is a big opportunity, with ethical and operational complexity

DCD heart transplantation is expanding through approaches like normothermic regional perfusion
(NRP) and ex vivo perfusion platforms. Early U.S. data and reports suggest high utilization of
recovered DCD hearts in experienced programsbut adoption varies, and ethics policies differ by
institution. When capability isn’t available, potential hearts may be recovered but not usedor
never recovered at all.

So… are these organs “wasted,” or are we being careful?

Sometimes discard is the right call. Not every recovered organ is safe to transplant. But the
uncomfortable middle is where the opportunity lives: organs declined due to inconsistent
evaluation, avoidable logistics, or fear of being penalized for outcomes.

A major expert consensus report has argued the U.S. should set aggressive goalslike reducing
kidney nonuse dramaticallybecause other systems achieve lower nonuse without unacceptable harm.
The point isn’t to “use everything.” It’s to stop losing viable organs to process failure.

What’s changing right now

Better use of “once-taboo” organs

One success story: kidneys from hepatitis C NAT-positive donors. As antiviral therapy became
routine in transplant protocols, nonuse of these kidneys dropped substantially compared to
earlier yearsshowing that “unusable” can become “usable” when medicine and practice evolve.

Policy modernization and accountability focus

Federal modernization efforts are placing more emphasis on patient safety, transparency,
technology reliability, and oversight. Recent oversight reports and reforms have highlighted
weaknesses in allocation services and the need for clearer accountabilityboth to protect patients
and to ensure donated organs are used as effectively as possible.

Machine perfusion and viability testing

Machine perfusion (hypothermic for kidneys; normothermic options for livers and other organs)
can reduce injury, provide better data, and sometimes turn a “maybe” into a “yes.” In real-world
practice, that can mean fewer last-minute discards, especially for DCD organs where time and
warm-ischemia injury are major concerns.

Standardizing kidney biopsy practices

There is active debateright nowabout when biopsies should be required and how to standardize
their use so they help decisions instead of becoming a convenient reason to decline.

What would reduce discards without compromising safety?

• Faster, smarter matching: reduce “offer ping-pong” by directing certain organs to
  programs that historically accept them and achieve good outcomes.
• Standardized evaluation: clearer biopsy standards, better imaging/lab protocols, and
  shared definitions of “acceptable risk.”
• More perfusion capacity: make machine perfusion and viability assessment more accessible
  beyond top-tier centers.
• Risk-sharing and metric reform: adjust outcome metrics so programs aren’t punished for
  helping sicker patients with higher-risk organs.
• Operational investments: transport reliability, OR capacity, staffing models, and better
  weekend/overnight coverage.
• Patient-informed choice: empower candidates to opt into higher-risk organs with informed
  consentbecause “waiting longer” has its own mortality risk.

Conclusion

Thousands of donated organs are discarded each year in the U.S. not because the country lacks
generosity, but because the system is complicated, time-sensitive, and sometimes set up to reward
caution over utilization. Some discards are medically necessary. Many appear to be “system
discards”the result of preventable logistics, inconsistent evaluation, and incentives that
quietly discourage reasonable risk-taking.

The good news is that the levers to reduce discards are visible: better data, better technology,
smarter allocation, standardized evaluation, and performance goals that push the system toward
using more viable organs safely. The best organ is the one that reaches a patient. The second
best organ is the one we stop losing to avoidable friction.

Experiences from the Front Lines (Composite, Based on Common Themes)

Note: The following experiences are compositesstitched from patterns commonly described by donor
families, coordinators, clinicians, and recipients. They’re not quotes from any one person, but
they reflect what many people say this process feels like.

1) The donor family who thought “yes” meant “used”

A donor’s family often expects a straight line: tragedy → generosity → lives saved. Then they
learn that an organ can be recovered and still not transplanted. The emotional math doesn’t
compute. “But we signed everything,” they might say. “We did the hard part.”

What they rarely see is the behind-the-scenes chaos: labs re-running results, transport updates,
a transplant center backing out because the intended recipient spiked a fever, another center
requesting a biopsy, and a surgeon trying to find an open operating room while three emergencies
collide. When an organ isn’t used, families can feel like their gift was rejected. Many OPO
coordinators describe spending time explaining that “not used” doesn’t mean “not valued”it can
mean safety, timing, or compatibility. Still, for families, it can reopen grief, because they
wanted something good to come from something awful.

2) The coordinator watching the clock and the decline list grow

Coordinators often describe organ placement like speed dating with a countdown timer. Calls go
out, programs review, questions come back: “Any hemodynamics? Latest ABG? Were antibiotics
started? Any vasopressors? Can we see the imaging?” Each answer is time. Each “no” is more time.

And the decline reasons can be maddeningly inconsistent. One center declines for donor age. The
next declines for a lab value that might normalize. Another says they can’t staff the case until
morning. Meanwhile, the organ’s cold time climbs. Coordinators describe the moment when an organ
becomes “late”not medically doomed, but increasingly hard to place because centers worry about
outcomes once ischemia time crosses a line. It’s not that people stop caring. It’s that the
window narrows until there’s no safe move left.

3) The transplant surgeon who has to say “no” for reasons that aren’t purely medical

Surgeons and teams may genuinely believe an organ could workand still decline. Maybe the
recipient is high-risk, the hospital is short on ICU beds, the OR schedule is packed, and the
team is already covering two other procurements. In that moment, “can we do it safely” becomes
the real question, and sometimes the honest answer is “not tonight.”

There’s also the outcomes pressure. Programs know their results are measured. A surgeon can feel
torn between two ethical goods: helping a patient now with a marginal organ, versus protecting
the program’s ability to serve many future patients by avoiding a case that could go poorly.
Clinicians describe this as “moral friction”not a lack of compassion, but competing
responsibilities inside a metric-driven system.

4) The patient who would have taken “imperfect” in a heartbeat

Many candidates on dialysis or with end-stage organ failure don’t crave perfection; they crave
time. They hear about discards and think, “I would have said yes.” But candidates don’t see every
offer, and they don’t always have the option to accept an organ their center won’t use.

Patients often describe living in a strange limbo: they’re told the system is fair, but they
learn outcomes and center behavior matter. Some switch centers to increase access to higher-risk
offers. Others can’t. The experience can feel like waiting for a ride-share that keeps canceling:
you keep refreshing, hoping the next one actually shows up. When an organ is discarded somewhere
else, the patient’s grief is quieter but sharp: another day on the list, another week of
treatments, another roll of the dice.